Selected Grants
Neutralizing Antibody Assessment to Support bnAb Production
ResearchPrincipal Investigator · Awarded by Advanced Bioscience Laboratories, Inc. · 2024 - 2028HVTN Lab Center: B Cell Supplement
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2024 - 2027CAVIMC 2022-2026 Grant Renewal
ResearchPrincipal Investigator · Awarded by Bill and Melinda Gates Foundation · 2016 - 2026Moderna mRNA 1273 P403-M (SARS Cov 2) Vaccine Trial Neutralizing Antibody Assessment and SARS-CoV-2 Variant Characterization and Validation
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2024 - 2026CISA 2023-03 Task 4 Lead - COVID immunogenicity
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2026Neutralizing Antibody Assessment for UVAX-HIV-101 Human Clinical Trial Study
ResearchCo Investigator · Awarded by Uvax Bio, LLC · 2024 - 2026HVTN Laboratory Center: Phase 1 PF
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2025HIV Vaccine Trials Network Laboratory Center
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2025Moderna mRNA1273 P403-M study Sub-protocol 2: A Phase 3b/4, Open-label Study to Assess the Immunogenicity of mRNA-1273.172 in Previously Vaccinated Adults Aged ¿18 years
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2024 - 2025Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2025CIVICs A - Option 18C
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025CIVICS A - Option 21A Equitable Adjustment
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025CIVICS A - Option 21A
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2025Neutralizing Antibody Assessment for SARS-CoV-2 Vaccine Trials
ResearchPrincipal Investigator · Awarded by Vaccine Company, Inc. · 2023 - 2025Nonhuman Primate Option 6
ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2025Moderma COVID/Flu 1083-P301
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2024 - 2025Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 5
ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2024CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024CISA COVID Peds Immunogenicity
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024CISA COVID Flu Immunogenicity
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024EQAPOL SARS CoV-2 Option 46
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2022 - 2024CISA Maternal COVID Immunogenicity
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2024A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2024HVTN Supplement 2022
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Center · 2022 - 2023A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023Moderna mRNA-1273 P201 (Part B) Trial Neutralizing Antibody Assessment
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023CIVICs A - Option 18B SAVE Aim 3
ResearchInvestigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2023A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2023EQAPOL SARS CoV-2 Option 44
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2021 - 2022A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A
ResearchPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2021 - 2022Neutralizing antibody assessment for EID 030 SARS-CoV-2 Vaccine Phase I trial
ResearchPrincipal Investigator · Awarded by Henry M. Jackson Foundation · 2021 - 2022CIVICs A - Option 18A SAVE Aims 1, 2
ResearchPrincipal Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2022CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022HVTN Laboratory Center: Phase 1 PF
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022CoVPN 5001 A prospective study of acute immune responses to SARS-CoV2 infection - LAB
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2022EQAPOL SARS CoV-2 EQA Option 43
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2021 - 2021EQAPOL SARS CoV-2 EQA Option 42
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2020 - 2021Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT
ResearchCollaborator · Awarded by National Institutes of Health · 2016 - 2021Primate Contract Expansion for Covid-19
ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2021Protocol Development Assays
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2019 - 2020HVTN Laboratory Center: HVTN 704
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2020HVTN Laboratory Center: HVTN Phase 1
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2020HVTN Laboratory Center: HVTN 118
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018HVTN Laboratory Center: HVTN 117
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2017 - 2018RAMP Scholar Award Shay Behrens
ResearchPrincipal Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2016 - 2018HIV Vaccine Trials Network: LC P5 PF
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2015 - 2018Nonhuman Primate Core-Option 6
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2018Option 13 Non Human Primate Core
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2018Option 19 Non Human Primate Core
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2017HIV Vaccine Trials Network: LC P5 PF
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015LC: HIV Vaccine Trials Network: Phase 1 PF
ResearchCo Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2015HIV Envelope-specific functional antibody responses in HIV-exposed, HIV-vaccinated infants
ResearchCollaborator · Awarded by National Institutes of Health · 2012 - 2015Methods to Determine HIV Transport and Inactivation by Microbicide Coating Layers
ResearchSignificant Contributor · Awarded by National Institutes of Health · 2009 - 2012Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2011 - 2012Central Laboratory for the HIV Vaccines Trial Network
ResearchCo Investigator · Awarded by National Institutes of Health · 2000 - 2006A Universal Env Immunogen for all HIV-1 Subtypes
ResearchConsultant · Awarded by National Institutes of Health · 2003 - 2006Same
ResearchAdministrative Assistant · Awarded by National Institutes of Health · 1997 - 2002Host Virus Interactions During Acute Infection
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1996 - 1999Perform Neutralizing Assays On Hiv,Siv,And Shiv, And Adopt
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1998External Relationships
- Moderna
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.